iPS Cell Selection via Gene Markers for Hematopoietic Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inducing differentiation of pluripotent stem cells into hematopoietic stem cells and progenitor cells are inefficient, and there is a need for more effective methods to select cells with high capacity for blood cell differentiation.
Innovation Solution
The method involves culturing pluripotent stem cells in the presence of insulin-like growth factor 2 (IGF2) and using specific gene expression and methylation state markers such as TRIM58, CTSF, FAM19A5, and TCERG1L to select and differentiate cells into hematopoietic stem cells and progenitor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods (embryoid body formation, co-culture with stromal cells, serum-free medium) are used to induce differentiation of ES cells or iPS cells into hematopoietic stem cells and/or hematopoietic progenitor cells, then differentiation can be achieved, but the efficiency is insufficient for medical treatment applications
Solution Approach 1:
The invention changes the chemical parameters of the culture medium by adding specific growth factors (SCF at 100-1000 ng/mL, TPO at 10-100 ng/mL, FLT3L at 10-100 ng/mL) to optimize differentiation efficiency. This parameter optimization enables reliable production of hematopoietic stem cells and progenitor cells suitable for medical treatment while maintaining high productivity.
2Productivity
If no selection method is used before differentiation induction, then all iPS cells are processed, but cells with low differentiation capacity are included, reducing overall efficiency
Solution Approach 1:
The invention performs preliminary selection of iPS cells based on their differentiation capacity before initiating the differentiation process. By pre-identifying cells with high hematopoietic differentiation potential, the method ensures that only capable cells are processed, thereby maximizing overall differentiation output and eliminating low-capacity cells that would reduce efficiency.
Data Source
AI summary
A method for producing hematopoietic stem cells and/or hematopoietic progenitor cells from pluripotent stem cells is described. The method includes a step of culturing pluripotent stem cells in the presence of IGF2. A method is described for selecting an induced pluripotent stem cell(s) having high capacity to differentiate into hematopoietic stem cells and/or hematopoietic progenitor cells, or into blood cells, based on the expression level(s) of one or more genes such as TRIM58, CTSF, FAM19A5, and TCERG1L genes, or on the DNA methylation state(s) of the TRIM58, CSMD1, and/or FAM19A5 gene(s).